Nonmyeloablative Allogeneic Stem Cell Transplantation for Relapsed Hodgkin's or Non-Hodgkin's Lymphoma After Autologous Transplantation (A BMT Study)

Relapsed lymphoma (diffuse large B-cell, follicular, primary mediastinal, mantle cell, small lymphocytic or Hodgkin's); >180 days after autologous bone marrow transplantation; must have received at least one cycle of chemotherapy post-ABMT relapse; must be in CR or PR with greatest disease measurement <= 2 cm; must have a genotypically HLA-identical sibling (5/6 or 6/6 match) or unrelated donor (10/10 match) who is medically fit, has signed consent to be a donor and meets donor eligibility criteria; >= 18 years of age; PS 0-2; must have ejection fraction >=40% by MUGA scan or 2d ECHO with no significant abnormalities; must have adequate pulmonary function measured by a correlated DLCO and TLC >= 40%; must not have a history of uncontrolled seizures; must not be HIV+ or with known AIDS syndrome; no prior malignancy except basal cell or squamous cell of the skin, in situ cervical cancer, adequately treated Stage I or II cancer for which patient is in CR, or any other cancer from which patient is disease free for >= 5 years; must not have had major surgery or radiotherapy w/in 4 weeks of registration; must not be pregnant or nursing; must not have uncompensated coronary artery disease on ECG or physical exam, or previous myocardial infarction, unstable angina, or uncontrolled atrial fibrillation in the past 6 months; must not have uncontrolled hypertension; must not have clinical evidence of severe peripheral vascular disease, diabetic ulcers or venous stasis ulcers, or a history of deep venous or arterial thrombosis w/in the last 3 months; must not be requiring continuous supplemental oxygen therapy; must not have clinical evidence of CNS involvement by lymphoma